hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06294405, orgStudyIdInfo id: 24-0010, briefTitle: Intraocular Lens Implant Registry Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-21, primaryCompletionDateStruct date: 2029-02-14, completionDateStruct date: 2029-02-14, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: University Hospital Augsburg, class: OTHER, descriptionModule briefSummary: The goal of this registry study is to optimize the results with intraocular lens implants used in cataract surgery., conditionsModule conditions: Intraocular Lens Complication, conditions: Intraocular Lens Rotation, conditions: Intraocular Lens Associated Postoperative Inflammation, conditions: Lens Opacities, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: OTHER, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: Intraocular lens Implantation, outcomesModule primaryOutcomes measure: Functional results with different Intraocular lenses, primaryOutcomes measure: Contrast sestivitiy with different Intraocular lenses, primaryOutcomes measure: Anatomical results., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Hospital Augsburg, status: RECRUITING, city: Augsburg, country: Germany, contacts name: Isabella Baur, MD, role: CONTACT, geoPoint lat: 48.37154, lon: 10.89851, hasResults: False
protocolSection identificationModule nctId: NCT06294379, orgStudyIdInfo id: OUH_SDM, briefTitle: Shared Decision Making in Melanoma Patients Receiving Adjuvant Therapy, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-03-01, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Odense University Hospital, class: OTHER, collaborators name: University of Copenhagen, collaborators name: Aarhus University Hospital, collaborators name: Aalborg University Hospital, descriptionModule briefSummary: This study aims to develop test and evaluate a Patient Decision Aid called "The Decision Helper" among melanoma patients eligible for adjuvant treatment.* Is the Decision Helper an acceptable tool for patients and clinicians and is it feasible in clinical practice?* Are there any differences in the levels of decisional regret in the patients who have not used the Decision Helper (pre-implementation) compared to the ones who have (post-implementation?, conditionsModule conditions: Malignant Melanoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, outcomesModule primaryOutcomes measure: Development of a Patient Decision Aid "The Decision Helper" for melanoma patients receiving adjuvant theory, primaryOutcomes measure: Evaluation of the "The Decision Helper", eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Odense University Hospital, status: RECRUITING, city: Odense C, zip: 5000, country: Denmark, contacts name: Lærke Tolstrup, role: CONTACT, phone: 40295129, email: lctolstrup@mail.dk, geoPoint lat: 55.39594, lon: 10.38831, hasResults: False
protocolSection identificationModule nctId: NCT06294366, orgStudyIdInfo id: MenoufiaU2022, briefTitle: Bipolar Transurethral Enucleation Versus Resection in the Treatment of Benign Prostatic Hyperplasia: a Comparative Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-06-12, primaryCompletionDateStruct date: 2024-04-12, completionDateStruct date: 2024-06-12, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Menoufia University, class: OTHER, descriptionModule briefSummary: Benign prostatic hyperplasia (BPH) is a common chronic progressive disease resulting in the enlargement of the prostate gland and bladder outlet obstruction in aging men .Because of the increasing aged population and advancements in diagnostic tools, the incidence and importance of BPH have increased . BPH can be treated either with watchful waiting, drug therapy, or surgery being the most effective treatment option for BPH .Transurethral resection of the prostate (TURP) has been recognized as the standard treatment for BPH with morbidity rate varies from 18% and 26% Until now, only open prostatectomy and transurethral Holmium laser enucleation of the prostate (HoLEP) have shown an equal efficacy and durability compared to TURP, conditionsModule conditions: Prostatic Hyperplasia, conditions: Prostate Enucleation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 52, type: ESTIMATED, armsInterventionsModule interventions name: Bipolar Bowa device, outcomesModule primaryOutcomes measure: Assessing and comparing the safety, the surgical efficacy and peri-operative morbidity of bipolar enucleation of the prostate and bipolar transurethral resection of the prostate for the treatment of patients with symptomatizing prostates., eligibilityModule sex: MALE, minimumAge: 50 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Faculty of medicine, status: RECRUITING, city: Shibīn Al Kawm, state: Menoufia, zip: 32866, country: Egypt, contacts name: Baher M Abdelraouf, MD, role: CONTACT, phone: +201069973254, email: maar2002002@gmail.com, geoPoint lat: 30.55258, lon: 31.00904, hasResults: False
protocolSection identificationModule nctId: NCT06294340, orgStudyIdInfo id: 1322-IX/42, briefTitle: Noise, Oxidative Stress and Cardiovascular System, acronym: NOXYCARD, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-01, primaryCompletionDateStruct date: 2027-12, completionDateStruct date: 2028-12, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: University of Belgrade, class: OTHER, descriptionModule briefSummary: Environmental noise represents a health problem for at least one in five citizens of the European Union. Noise exposure leads to the development of arterial hypertension, myocardial infarction, stroke, and obesity. Given the limited information on noise exposure and noise effects on humans in the Republic of Serbia, the overall objective of NOXYCARD is to collect environmental noise levels data; to identify long-term and short-term noise effects on the cardiovascular system; and to evaluate the levels of blood stress hormones, oxidative stress, and inflammation in individuals with normal body weight and individuals with obesity., conditionsModule conditions: Noise; Adverse Effect, conditions: Noise Exposure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Exposure to loud pre-recorded road traffic noise, outcomesModule primaryOutcomes measure: Systolic blood pressure, primaryOutcomes measure: Concentration of stress hormone, secondaryOutcomes measure: Diastolic blood pressure, secondaryOutcomes measure: Concentration of inflammation parameters, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Faculty of Medicine, University of Belgrade, city: Belgrade, state: Beograd, zip: 11040, country: Serbia, geoPoint lat: 44.80401, lon: 20.46513, hasResults: False
protocolSection identificationModule nctId: NCT06294314, orgStudyIdInfo id: 1982669-3, briefTitle: Return to Play After ACL Reconstruction With Bone Marrow Aspirate, DBM, and an Internal Brace, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-26, primaryCompletionDateStruct date: 2026-08-01, completionDateStruct date: 2028-07-01, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Marshall University, class: OTHER, collaborators name: Arthrex, Inc., descriptionModule briefSummary: The Investigators are studying the effect of an ACL reconstruction on return to play by capturing outcome measures and biomechanics information., conditionsModule conditions: Anterior Cruciate Ligament Rupture, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 450, type: ESTIMATED, armsInterventionsModule interventions name: Fertilized ACL, outcomesModule primaryOutcomes measure: Return to play, primaryOutcomes measure: Biomechanics testing, secondaryOutcomes measure: MRI findings, otherOutcomes measure: Rerupture, eligibilityModule sex: ALL, minimumAge: 14 Years, maximumAge: 26 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Marshall University, status: RECRUITING, city: Huntington, state: West Virginia, zip: 25755, country: United States, contacts name: chad d lavender, md, role: CONTACT, phone: 304-552-6514, email: doclav@gmail.com, contacts name: Kara Cipriani, np, role: CONTACT, phone: 304-541-5316, email: cipriani6@marshall.edu, geoPoint lat: 38.41925, lon: -82.44515, hasResults: False
protocolSection identificationModule nctId: NCT06294301, orgStudyIdInfo id: P10-LP005-01, briefTitle: A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-19, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2024-10-30, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Longbio Pharma, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-005 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-005 and Part 2, multiple ascending dose (MAD)., conditionsModule conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH), designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 78, type: ESTIMATED, armsInterventionsModule interventions name: LP-005 Dose 1 (Single), interventions name: LP-005 Dose 2 (Single), interventions name: LP-005 Dose 3 (Single), interventions name: LP-005 Dose 4 (Single), interventions name: LP-005 Dose 5 (Single), interventions name: LP-005 Dose 6 (Single), interventions name: Placebo (Single), interventions name: LP-005 Dose 7 (Multiple), interventions name: LP-005 Dose 8 (Multiple), interventions name: LP-005 Dose 9 (Multiple), interventions name: Placebo (Multiple), outcomesModule primaryOutcomes measure: Adverse events, secondaryOutcomes measure: Time to peak concentration (Tmax) of LP-005, secondaryOutcomes measure: Maximum concentration (Cmax) of LP-005, secondaryOutcomes measure: Elimination half-life (t1/2) of LP-005, secondaryOutcomes measure: Area under the concentration-time curve (AUC0-t) of LP-005, secondaryOutcomes measure: Apparent clearance rate (CL/F) of LP-005, secondaryOutcomes measure: Assessment of immunogenicity, secondaryOutcomes measure: Assessment of complement C5 activity, secondaryOutcomes measure: Assessment of complement C3b activity, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Shanghai Public Health Clinical Center, status: RECRUITING, city: Shanghai, state: Shanghai, country: China, contacts name: Yun Ling, role: CONTACT, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06294288, orgStudyIdInfo id: P-10-LP003-2022-01, briefTitle: A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2021-07-01, primaryCompletionDateStruct date: 2023-09-03, completionDateStruct date: 2024-03-15, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Longbio Pharma, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-003 and Part 2, multiple ascending dose (MAD)., conditionsModule conditions: Chronic Spontaneous Urticaria, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: LP-003 Dose 1 (Single), interventions name: LP-003 Dose 2 (Single), interventions name: LP-003 Dose 3 (Single), interventions name: LP-003 Dose 4 (Single), interventions name: LP-003 Dose 5 (Single), interventions name: Placebo (Single), interventions name: LP-003 Dose 6 (Multiple), interventions name: LP-003 Dose 7 (Multiple), interventions name: LP-003 Dose 8 (Multiple), interventions name: Placebo (Multiple), outcomesModule primaryOutcomes measure: Adverse events, secondaryOutcomes measure: Time to peak concentration (Tmax) of LP-003, secondaryOutcomes measure: Maximum concentration (Cmax) of LP-003, secondaryOutcomes measure: Elimination half-life (t1/2) of LP-003, secondaryOutcomes measure: Area under the concentration-time curve (AUC0-t) of LP-003, secondaryOutcomes measure: Apparent clearance rate (CL/F) of LP-003, secondaryOutcomes measure: Assessment of immunogenicity, secondaryOutcomes measure: Assessment of total immunoglobulin E (IgE), secondaryOutcomes measure: Assessment of free IgE, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Shanghai General Hospital, city: Shanghai, state: Shanghai, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06294275, orgStudyIdInfo id: P-10-LP001-2022-01, briefTitle: A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-09-16, primaryCompletionDateStruct date: 2024-01-02, completionDateStruct date: 2024-04-06, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Longbio Pharma, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-001 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-001 and Part 2, multiple ascending dose (MAD)., conditionsModule conditions: Myelodysplastic Syndrome (MDS), designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 68, type: ESTIMATED, armsInterventionsModule interventions name: LP-001 Dose 1 (Single), interventions name: LP-001 Dose 2 (Single), interventions name: LP-001 Dose 3 (Single), interventions name: LP-001 Dose 4 (Single), interventions name: LP-001 Dose 5 (Single), interventions name: LP-001 Dose 6 (Single), interventions name: Placebo (Single), interventions name: LP-001 Dose 7 (Multiple), interventions name: LP-001 Dose 8 (Multiple), interventions name: Placebo (Multiple), outcomesModule primaryOutcomes measure: Adverse events, secondaryOutcomes measure: Time to peak concentration (Tmax) of LP-001, secondaryOutcomes measure: Maximum concentration (Cmax) of LP-001, secondaryOutcomes measure: Elimination half-life (t1/2) of LP-001, secondaryOutcomes measure: Area under the concentration-time curve (AUC0-t) of LP-001, secondaryOutcomes measure: Apparent clearance rate (CL/F) of LP-001, secondaryOutcomes measure: Assessment of immunogenicity, secondaryOutcomes measure: Assessment of hemoglobin (Hb) change, secondaryOutcomes measure: Assessment of red blood cell (RBC) count change, secondaryOutcomes measure: Assessment of reticulocyte (Rtc) count change, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Shanghai Public Health Clinical Center, city: Shanghai, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06294262, orgStudyIdInfo id: 2023-508230-33-00, briefTitle: Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine, acronym: TETRALITE-Ib, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-29, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: LiteVax BV, class: INDUSTRY, collaborators name: University Hospital, Ghent, collaborators name: HarmonyCR, Melle, Belgium, descriptionModule briefSummary: The effect of LiteVax Adjuvant supplemented to licensed seasonal influenza vaccine on safety and immunogenicity will be investigated in both younger and older healthy participants. Local and systemic adverse events, and humoral and cellular immune responses will be determined at different time intervals after a single administration. Mode of action of LiteVax Adjuvant will examined by detailed genetic analysis and omics approaches such as transcriptomics, proteomics and metabolomics., conditionsModule conditions: Vaccination Reaction, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 84, type: ESTIMATED, armsInterventionsModule interventions name: TETRALITE, outcomesModule primaryOutcomes measure: Characterise local and systemic AEs, and SAEs, pIMDs and AESIs to TETRALITE, primaryOutcomes measure: Characterise clinical hematology and biochemistry to TETRALITE, secondaryOutcomes measure: Characterise HI antibody response to the four vaccine strains of TETRALITE in serum, secondaryOutcomes measure: Characterise MN antibody response to the four vaccine strains of TETRALITE in serum, otherOutcomes measure: Characterise mechanisms of action of LiteVax Adjuvant, otherOutcomes measure: Characterise T-cell responses to TETRALITE in PBMCs, otherOutcomes measure: Characterise B-cell response to TETRALITE in PBMCs, otherOutcomes measure: Characterise molecular features of vaccine-induced immunity by RNA sequencing, otherOutcomes measure: Characterise antibody response to influenza virus antigens other than hemaglutunin of the vaccine strains of TETRALITE, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Hospital Gent, status: RECRUITING, city: Ghent, zip: 9000, country: Belgium, geoPoint lat: 51.05, lon: 3.71667, hasResults: False
protocolSection identificationModule nctId: NCT06294249, orgStudyIdInfo id: 20045125, briefTitle: Pain Severity in Flapless Dental Implant Placement Using Laser, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-01-01, primaryCompletionDateStruct date: 2023-12-01, completionDateStruct date: 2023-12-04, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Shiraz University of Medical Sciences, class: OTHER, collaborators name: Shahid Beheshti University of Medical Sciences, descriptionModule briefSummary: The goal of this split-mouth randomized clinical trial study was to investigate the effect of using a laser on pain and discomfort following flapless dental implant surgery. It was hypothesized that laser did not have any impact on post-op pain. Therefore, the study aimed to compare pain and discomfort following flapless dental implant surgeries with or without a laser., conditionsModule conditions: Jaw, Edentulous, Partially, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: Laser-induced Incision, interventions name: Punch Incision, interventions name: Implant Placement, outcomesModule primaryOutcomes measure: Pain Severity, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: shiraz University of medical sciences, city: Shiraz, state: Fars, country: Iran, Islamic Republic of, geoPoint lat: 29.61031, lon: 52.53113, hasResults: False